Petrella Tony, Comeau Michael R, Maynadié Marc, Couillault Gérard, De Muret Anne, Maliszewski Charles R, Dalac Sophie, Durlach Anne, Galibert Laurent
Centre de Pathologie of Dijon and the Department of Pathology, Dijon University Hospital, France.
Am J Surg Pathol. 2002 Jul;26(7):852-62. doi: 10.1097/00000478-200207000-00003.
In 1999, we reported seven cases of an unusual hematologic malignancy with primary cutaneous presentation that appeared as a distinct clinicopathologic entity characterized by medium-sized tumor cells with a peculiar CD3- CD4+ CD56+ CD43+ HLA-DR+ cell surface phenotype. Because the origin of tumor cells was not clear and they exhibited a nonlineage-specific phenotype, we hypothesized that such tumors likely originated from hematologic-myeloid precursor cells and were tentatively assigned the designation "agranular CD4+ CD56+ hematodermic neoplasms." In the present study we report 14 cases (seven already reported and seven additional cases) of these tumors, and simultaneously we present now a rare population of cells that we have identified in the peripheral blood of healthy volunteers treated with Flt3 ligand. These cells express all the characteristic markers of CD4+ CD56+ hematodermic neoplasms. This population appears to be related to plasmacytoid monocytes because they also expressed CD68 and bright levels of CD123. To confirm the relationship between these normal cells and CD4+ CD56+ hematodermic neoplasms, we conducted an extensive comparative phenotypic study. Results show that these two cell types are indeed related because they share many phenotypic features, including the presence of CD4, CD56, CD43, CD68, and HLA-DR and the absence of other T, B, NK, or myelomonocytic markers. More importantly, we found that the bright expression of CD123 by immunohistochemistry is a distinctive characteristic of CD4+ CD56+ hematodermic neoplasms because all (n = 14) cases expressed this marker, whereas only two specimens in a control panel comprising 30 samples of related tumors expressed comparable levels of CD123. We therefore propose that oncogenic transformation of NCAM-expressing plasmacytoid monocyte-like cells may lead to "agranular CD4+ CD56+ hematodermic neoplasm."
1999年,我们报告了7例以原发性皮肤表现为主的罕见血液系统恶性肿瘤病例,这些病例表现为一种独特的临床病理实体,其特征为中等大小的肿瘤细胞,具有特殊的CD3-CD4+CD56+CD43+HLA-DR+细胞表面表型。由于肿瘤细胞的起源尚不清楚,且它们表现出非谱系特异性表型,我们推测此类肿瘤可能起源于血液-髓系前体细胞,并暂时命名为“无颗粒CD4+CD56+血液皮肤肿瘤”。在本研究中,我们报告了这些肿瘤的14例病例(7例已报告,7例新增病例),同时展示了我们在接受Flt3配体治疗的健康志愿者外周血中鉴定出的一群罕见细胞。这些细胞表达CD4+CD56+血液皮肤肿瘤的所有特征性标志物。这群细胞似乎与浆细胞样单核细胞有关,因为它们也表达CD68和高水平的CD123。为了证实这些正常细胞与CD4+CD56+血液皮肤肿瘤之间的关系,我们进行了广泛的比较表型研究。结果表明,这两种细胞类型确实相关,因为它们具有许多共同的表型特征,包括CD4、CD56、CD43、CD68和HLA-DR的存在以及其他T、B、NK或髓单核细胞标志物的缺失。更重要的是,我们发现通过免疫组织化学检测,CD123的明亮表达是CD4+CD56+血液皮肤肿瘤的一个独特特征,因为所有14例病例均表达该标志物,而在由30个相关肿瘤样本组成的对照组中,只有2个样本表达了相当水平的CD123。因此,我们提出表达NCAM的浆细胞样单核细胞样细胞的致癌转化可能导致“无颗粒CD4+CD56+血液皮肤肿瘤”。